Anti-CCP Test (Rheumatoid Arthritis)

Comparing the Two Tests

Non-RA Causes of Positive RF

• Sjögren's syndrome
• SLE (lupus)
• Infection (subacute bacterial endocarditis, hepatitis C, TB)
• Other connective tissue diseases
• Healthy elderly: up to 5% of those >70 years
• Cryoglobulinaemia

Anti-CCP vs rheumatoid factor vs ESR/CRP: how they compare

Anti-CCP is the most specific blood test for rheumatoid arthritis, but it is usually ordered as part of an arthritis workup. Each test answers a different question:

Anti-CCP plus RF together give the clearest serological picture — but joint examination and imaging still carry the diagnosis.

Reading your report: what your doctor actually looks at

When a doctor opens an anti-CCP result, the number itself is only the starting point. Here is the checklist they run through — and the same checklist helps you read your own report calmly:

1. Positive or negative comes first. A clearly positive anti-CCP is strongly associated with rheumatoid arthritis; a borderline value is usually repeated or read with extra caution.
2. What do the joints say? Antibodies support the diagnosis, but swollen, tender small joints — especially symmetric ones in the hands — are what the result is matched against.
3. What does RF add? Anti-CCP positive plus RF positive is the classic RA serology; anti-CCP positive with negative RF still points firmly at RA, since anti-CCP is the more specific of the two.
4. A negative result is not a clean chit. Early RA can be seronegative — symptoms with negative antibodies still deserve a rheumatologist's assessment, not dismissal.
5. The titre is not for monitoring. Unlike CRP, anti-CCP levels are not used to track disease activity or adjust treatment — repeating it to “see if it's better” is not useful.

A positive anti-CCP is a strong clue, not a sentence: early treatment changes outcomes in RA, which is exactly why the result should reach a rheumatologist promptly. Discuss the full picture with your doctor.

Anti-CCP test price in India: typical bands across major lab chains

Anti-CCP is a specialised antibody assay, priced above routine blood tests. Typical list-price bands:

These are approximate bands, not quotes: prices change often and vary by city, and home collection can add a small fee. Where possible, choose a NABL-accredited lab, and remember the reference range printed on your own report is the one that counts.

Frequently Asked Questions

Pharmacist's practical notes

Anti-CCP's value is its specificity: among arthritis blood tests, it is the one most tightly linked to rheumatoid arthritis. That also makes a positive result frightening — but remember it is a risk marker and diagnostic clue, not a measure of damage done. What happens next is a rheumatologist's assessment, ideally soon, because early RA treatment changes the long-term picture.

Do not use the antibody level to judge whether treatment is working: anti-CCP titres do not track disease activity the way CRP does. Doctors monitor symptoms, joint counts and inflammation markers instead — repeating anti-CCP for reassurance wastes a test.

In India

Indian labs usually report anti-CCP in U/mL (or AU/mL). The test typically costs &rupee;1,000–&rupee;2,000, though prices vary by city and lab; arthritis workups often bundle it with RF, CRP and ESR.

Where possible, choose a NABL-accredited lab. Assay methods differ between labs, so the cutoff printed on your own report is the one that governs.

References

Sources cited on this page. PubMed links open the original abstract.

1. Schellekens GA, Visser H, de Jong BA, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum. 2000;43(1):155–163. PMID 10643712 · doi:10.1002/1529-0131(200001)43:1<155::AID-ANR20>3.0.CO;2-3
2. Rönnelid J, Hansson M, Mathsson-Alm L, et al. Autoantibodies in Rheumatoid Arthritis – Laboratory and Clinical Perspectives. Front Immunol. 2021;12:685312. PMID 34054878 · doi:10.3389/fimmu.2021.685312
3. Motta F, Alongi F, Bruni C, et al. Rheumatoid factor isotypes in rheumatoid arthritis diagnosis and prognosis: a systematic review and meta-analysis. RMD Open. 2023;9(2):e002817. PMID 37541740 · doi:10.1136/rmdopen-2022-002817

Why anti-CCP is more specific than rheumatoid factor

Rheumatoid factor (RF) was the first autoantibody discovered in rheumatoid arthritis, but it has significant limitations: it is positive in only 70–80% of RA patients (RF-negative RA exists), and it is also positive in many other conditions, hepatitis C, Sjögren's syndrome, SLE, sarcoidosis, infective endocarditis, and in 5–10% of healthy older adults.³ This low specificity reduces its diagnostic value.

Anti-CCP antibodies (anti-cyclic citrullinated peptide, also called anti-citrullinated protein antibodies, ACPA) are far more specific for RA: they appear in around 70–75% of RA patients but in fewer than 2% of healthy individuals. Their high specificity (approximately 95–98%) means a positive anti-CCP result is strong evidence for RA, not merely "possible RA".

The two tests complement each other. Approximately 30% of RA patients are seronegative for RF but seropositive for anti-CCP, and vice versa in a small proportion.² Measuring both together maximises sensitivity, a patient positive for either or both has a high probability of RA. Positivity for both simultaneously is found in about 50–60% of RA patients and is associated with more aggressive disease and greater joint damage.

Anti-CCP and prognosis, predicting joint damage

Anti-CCP antibodies can appear in the bloodstream 5–10 years before clinical symptoms of RA develop. This pre-clinical window has important implications: high anti-CCP levels in a person with new-onset joint symptoms predict a more aggressive course with faster erosion and joint destruction.

In clinical practice, anti-CCP titre (level) influences treatment decisions. A very high anti-CCP (more than 3 times the upper limit of normal) is associated with:

• More rapid radiographic progression (joint erosion visible on X-ray)
• Higher likelihood of requiring biologic therapy (such as TNF inhibitors or JAK inhibitors) in addition to standard DMARDs (methotrexate)
• Greater systemic manifestations (rheumatoid nodules, vasculitis)

This is why rheumatologists use anti-CCP not just for diagnosis but as part of risk stratification. It informs how aggressively to treat from the outset and supports the "treat to target" strategy in early RA, aiming for remission or low disease activity to prevent permanent joint damage.